1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid | 1131912-88-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
• 英文别名: 1-methylpyrazolo[3,4-b]pyridine-5-carboxylic acid
• CAS: 1131912-88-3
• 化学式: C₈H₇N₃O₂
• mdl: MFCD11043028
• 分子量: 177.162
• InChiKey: GZBXJRACVPGWTE-UHFFFAOYSA-N

物化性质

• 沸点：
  404.4±25.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 在 吡啶 、 1-氯-N,N,2-三甲基丙烯胺 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.17h， 生成 5-fluoro-2-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)oxazolo[5,4-b]pyridine
  参考文献：
  名称：

  Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328

  摘要：

  5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential F-18 containing beta-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human beta-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of beta-amyloid plaque load.

  DOI：

  10.1021/ml200018n

文献信息

• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102303A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.

  化合物的结构式（I）和结构式（II），含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法，例如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症）、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。
• PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS
  申请人：Glaxo Group Limited

  公开号：EP2049534A1

  公开（公告）日：2009-04-22
• [EN] PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS<br/>[FR] COMPOSÉS
  申请人：GLAXO GROUP LTD

  公开号：WO2008009735A1

  公开（公告）日：2008-01-24

  [EN] The present invention provides a compound of formula (I) or a salt thereof (in particular, a pharmaceutically acceptable salt thereof): The invention also provides the use of the compounds or salts as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis, e.g. in a mammal such as a human.
  [FR] La présente invention concerne un composé représenté par la formule (I) ou un sel de ce dernier( notamment un sel pharmaceutiquement acceptable de ce dernier). Cette invention porte également sur l'utilisation des composés ou des sels selon l'invention en tant qu'inhibiteurs de la phosphodiestérase de type IV (PDE4) et/ou pour le traitement et/ou la prévention des maladies inflammatoires et/ou allergiques telles que la maladie pulmonaire obstructive chronique (MPOC), l'asthme, la rhinite (par exemple la rhinite allergique), la dermatite atopique ou le psoriasis, par exemple chez un mammifère tel que l'homme.